![](/img/cover-not-exists.png)
Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies
Ardini, Elena, Siena, SalvatoreVolume:
5
Journal:
ESMO Open
DOI:
10.1136/esmoopen-2020-000867
Date:
September, 2020
File:
PDF, 976 KB
2020